Related Funds
| Fund Name | Location |
| AB Capital Group | - |
| Amatil X Ventures | Australia, New South Wales, North Sydney |
| Asia PropTech | China, Hong Kong, Hong Kong Island |
| Bio-sight Capital | Ibaraki, Japan, Osaka Prefecture |
| Chengdu Zhengjian | Chengdu, China, Sichuan |
| Desai Capital Management | - |
| Growth Catalyst Partners | Chicago, Illinois, United States |
| Howell Capital | California, San Francisco, United States |
| IBT Management Corporation | Taipei, Taiwan |
| LearnStart | New York, New York, United States |
| Mavrik | - |
| Script Capital | France, Ile-de-France, Paris |
| Sevenwoods Investment | Chiba Prefecture, Japan, Tateyama |
| Shanghai-Israel Investment Fund | - |
| Sydes | - |
| The Home Depot | Atlanta, Georgia, United States |
| Tolero Ventures | California, Los Angeles, United States |
| U.S. Bank Trust National Association | Delaware, United States, Wilmington |
| Withfounders | Italy, Lombardia, Milano |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Seed Therapeutics | $24M | 06 Aug 2024 | New York, New York, United States | ||
Casma Therapeutics | $46M | 15 Nov 2022 | Cambridge, Massachusetts, United States | ||
Ractigen Therapeutics | $30M | 27 Jan 2022 | Nantong, Jiangsu, China | ||
PRISM BioLab | $15M | 12 Oct 2021 | Fujisawa, Kanagawa Prefecture, Japan | ||
Neuroglee Therapeutics | $10M | 09 Sep 2021 | Singapore, Central Region, Singapore | ||
ŌURA | $100M | 04 May 2021 | Oulu, Oulu, Finland | ||
Allm | $50M | 05 Apr 2021 | Chiyoda, Japan | ||
Neuroglee Therapeutics | $2M | 03 Dec 2020 | Singapore, Central Region, Singapore | ||
| $3M | 05 Nov 2020 | San Francisco, California, United States |
– Neuroglee Therapeutics, a startup developing digital therapeutics for people with neurodegenerative diseases, has raised a $10m Series A led by Openspace Ventures and EDBI.
– The funding will be used to launch virtual neurology clinics and to support Neuroglee’s move to Boston.
– Other participants included Ramen Singh, the former chief executive officer of Mundipharma; Biofourmis co-founders Kuldeep Singh Rajput and Wendou Liu; and Eisai, the Japanese pharmaceutical that led Neuroglee’s last round last year.
– Neuroglee’s adaptive learning tech uses machine learning and biomarkers related to cognitive function, mood and behavior to automatically personalize therapy plans for each patient, who access the software through a smartphone or tablet.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Seed Therapeutics | $24M | 06 Aug 2024 | New York, New York, United States | ||
Casma Therapeutics | $46M | 15 Nov 2022 | Cambridge, Massachusetts, United States | ||
Ractigen Therapeutics | $30M | 27 Jan 2022 | Nantong, Jiangsu, China | ||
PRISM BioLab | $15M | 12 Oct 2021 | Fujisawa, Kanagawa Prefecture, Japan | ||
Neuroglee Therapeutics | $10M | 09 Sep 2021 | Singapore, Central Region, Singapore | ||
ŌURA | $100M | 04 May 2021 | Oulu, Oulu, Finland | ||
Allm | $50M | 05 Apr 2021 | Chiyoda, Japan | ||
Neuroglee Therapeutics | $2M | 03 Dec 2020 | Singapore, Central Region, Singapore | ||
| $3M | 05 Nov 2020 | San Francisco, California, United States |
